about
High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in manQuantitative cross-species extrapolation between humans and fish: the case of the anti-depressant fluoxetineUsing data from drug discovery and development to aid the aquatic environmental risk assessment of human pharmaceuticals: concepts, considerations, and challenges.Development of a common carp (Cyprinus carpio) pregnane X receptor (cPXR) transactivation reporter assay and its activation by azole fungicides and pharmaceutical chemicals.Environmental endocrine disrupters dysregulate estrogen metabolism and Ca2+ homeostasis in fish and mammals via receptor-independent mechanisms.Effects of the lipid regulating drug clofibric acid on PPARĪ±-regulated gene transcript levels in common carp (Cyprinus carpio) at pharmacological and environmental exposure levels.Interference with xenobiotic metabolic activity by the commonly used vehicle solvents dimethylsulfoxide and methanol in zebrafish (Danio rerio) larvae but not Daphnia magnaAcute and chronic effects of carrier solvents in aquatic organisms: a critical review.Complex physiological traits as biomarkers of the sub-lethal toxicological effects of pollutant exposure in fishes.Approaches to seizure risk assessment in preclinical drug discovery.Chronic effects assessment and plasma concentrations of the beta-blocker propranolol in fathead minnows (Pimephales promelas).Validation of the use of zebrafish larvae in visual safety assessment.4-dimensional functional profiling in the convulsant-treated larval zebrafish brain.No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans.In vivo and in vitro liver and gill EROD activity in rainbow trout (Oncorhynchus mykiss) exposed to the beta-blocker propranolol.Benefits of the maximum tolerated dose (MTD) and maximum tolerated concentration (MTC) concept in aquatic toxicology.Plasma concentrations of arginine vasotocin and urotensin II are reduced following transfer of the euryhaline flounder (Platichthys flesus) from seawater to fresh water.Anti-anxiety drugs and fish behavior: Establishing the link between internal concentrations of oxazepam and behavioral effects.Tissue levels and biomarkers of organic contaminants in feral and caged chub (Leuciscus cephalus) from rivers in the West Midlands, UK.A multi-endpoint in vivo larval zebrafish (Danio rerio) model for the assessment of integrated cardiovascular function.Defining the chronic impacts of atenolol on embryo-larval development and reproduction in the fathead minnow (Pimephales promelas).Cloning of a chub metallothionein cDNA and development of competitive RT-PCR of chub metallothionein mRNA as a potential biomarker of heavy metal exposure.Ototoxin-induced cellular damage in neuromasts disrupts lateral line function in larval zebrafish.DNA strand breaks and adducts determined in feral and caged chub (Leuciscus cephalus) exposed to rivers exhibiting variable water quality around Birmingham, UK.Author Correction: 4-dimensional functional profiling in the convulsant-treated larval zebrafish brainDoes exhaustive exercise result in oxidative stress and associated DNA damage in the chub (Leuciscus cephalus)?A Homologous Radioimmunoassay for the Measurement of Urotensin II in the Euryhaline Flounder,Platichthys flesusBioavailability of the imidazole antifungal agent clotrimazole and its effects on key biotransformation genes in the common carp (Cyprinus carpio)Formation of micronuclei in erythrocytes of the fathead minnow (Pimephales promelas) after acute treatment with mitomycin C or cyclophosphamideEstrogenic Mechanisms and Cardiac Responses Following Early Life Exposure to Bisphenol A (BPA) and Its Metabolite 4-Methyl-2,4-bis(p-hydroxyphenyl)pent-1-ene (MBP) in ZebrafishCardiovascular effects and molecular mechanisms of bisphenol A and its metabolite MBP in zebrafishThe use of diffusive gradients in thin-film (DGT) passive samplers for the measurement of bioavailable metals in river waterTesting the Translational Power of the Zebrafish: An Interspecies Analysis of Responses to Cardiovascular Drugs
P50
Q28192315-31072BDB-5BAD-4887-9EC1-68C58C8FA8F3Q28543995-C0AE9B86-CDCA-4E60-9011-8C40E5C0A6CBQ33475057-574A98CC-1C12-4B91-897D-9E5C7DD672B8Q33835410-5E01C603-ABC1-4A0D-B050-8DCB077CCD1FQ35119785-077CD1F4-97D4-42F9-AF21-A724DEA13DE2Q35214980-2DD383B9-0C1C-4F39-BA62-2F7CE593CB4AQ36150610-20F13707-D9D0-4BEE-9EDF-5E12B003C666Q36313821-8F5C9BE6-3E37-48B7-9D74-1F95A7B79C5DQ36742668-55409681-856C-4257-AC24-CDC0BD5D4595Q37527181-D6526F5E-D0F0-49C9-AB33-F2CD382FDC18Q38433896-B2C6BCDA-1DD0-4EA1-9C23-A4F8E69EA31FQ40082869-A0AAD31C-5E61-452A-875D-58D6CA75EAF0Q41140436-FC3BADC9-1117-4BA1-BB11-A992D9852571Q42284302-7321B70F-0108-4103-9F2F-9311F7AA0ED4Q42746972-4A134A9A-925B-4E80-8D5A-209A5F8600D4Q43794883-278260B7-373D-45D5-99A9-FC1037CF700FQ43874981-C55FA64D-7415-4F27-93EC-7E207942D56CQ46472250-C9A7191B-B046-404B-9EDE-24FDCEB7D552Q46527288-F511B936-90B0-409C-8551-FF9D70F598C4Q46781918-77880700-77BC-4E5D-AA74-669E5A05310AQ46819423-D7BE8A3E-5D82-44E5-B2E8-2FB3F6D480A6Q47394047-A1FA2324-813B-4F43-9D28-2807890C89EDQ50432199-8746CEA1-308D-47C8-A569-1B6DD4908DE2Q52650082-DA65C3E0-D7D7-48AC-AB54-E421AD5D6FDAQ57799974-441002E0-5265-4EEC-92BF-4E550FCB1E6DQ57916307-3D8086B6-ECAB-4BF6-A85D-F4B621A1AF22Q57918050-EAAB9E6F-E846-4499-8FEE-9B4BF0318AADQ57931547-31B74DC7-1ADC-4641-978E-49069C5D02BEQ57939206-2C6A21C9-8855-45E3-8539-3AA8135A7A18Q57948248-D95762EA-A9A6-4061-A6E0-81D11B4F1EA3Q60912495-DEDE909C-2C99-4052-B181-749C5103153DQ80525477-121A94C2-87BE-4529-B7CF-BA25CE1A353AQ93046946-1D5C4713-530B-4C71-A47D-D5AE50E3B337
P50
description
researcher
@en
wetenschapper
@nl
name
Matthew Winter
@en
Matthew Winter
@nl
type
label
Matthew Winter
@en
Matthew Winter
@nl
prefLabel
Matthew Winter
@en
Matthew Winter
@nl
P108
P106
P31
P496
0000-0002-3668-6564